Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Anti-CaSR IgG ELISA Kit

CaSR IgG Reactivity: Human Colorimetric Sandwich ELISA 0-270 U/mL Plasma, Serum
Catalog No. ABIN1305169
  • Target See all Anti-CaSR IgG (CaSR IgG) products
    Anti-CaSR IgG (CaSR IgG) (Anti-Calcium Sensing Receptor IgG Antibody (CaSR IgG))
    Reactivity
    Human
    Detection Method
    Colorimetric
    Method Type
    Sandwich ELISA
    Detection Range
    0-270 U/mL
    Minimum Detection Limit
    0 U/mL
    Application
    ELISA
    Purpose
    This ELISA (enzyme-linked immunosorbent assay) kit is producedfor the quantitative determination of human anti-CaSR (calciumsensing receptor) autoantibody levels in serum, plasma, tissueextract or other liquid samples. The detection of this autoantibody isclinical useful in the aid of diagnosis of autoimmune sporadichypoparathyroidism, autoimmune polyendocrinepathy syndrome,acquired hypocalciuric hypercalcemia, as well as other autoimmuneparathyroid diseases.
    Brand
    ED™
    Sample Type
    Serum, Plasma
    Analytical Method
    Quantitative
    Characteristics
    Calcium & Bone Metabolism / Autoimmune Disease
    Components
    1. Human CaSR Antigen Coated Microplate. One bottle contains 12 mL of 0.5 M sulfuric acid. This reagent should be stored at 2-8 °C or room temperature and is stable until the expiration date on the kit box
    Human CaSR IgG Standards. Five vials each contain assay standards in a liquid bovine serum based matrix with a non-azide preservative. Refer to vial for exact concentration for each standard. All standards should be stored at 2-8 °C and are stable until the expiration date on the kit box
    Human CaSR IgG Controls. Two vials each contains assay controls in a liquid bovine serum based matrix with a non azide preservative. Refer to vials for exact concentration range for each control. Both controls should be stored at 2-8 °C and are stable until the expiration date on the kit box.
    Material not included
    1. Precision single channel pipettes capable of delivering 10 μL, 25 μL, 100 μL, and 1000 μL
    2. Repeating dispenser suitable for delivering 100 μL
    3. Disposable pipette tips suitable for above volume dispensing
    4. Disposable 12 x 75 mm glass or plastic tubes
    5. Disposable plastic 1000 mL bottle with caps
    6. Aluminum foil
    7. Plastic microtiter well cover or polyethylene film
    8. ELISA multichannel wash bottle or automatic (semi-automatic) washing system
    9. Spectrophotometric microplate reader capable of reading absorbance at 450 nm.
  • Sample Volume
    10 μL
    Assay Time
    4 h
    Plate
    Pre-coated
    Protocol
    This ELISA is designed, developed and produced for the quantitativemeasurement of human anti-CaSR autoantibody (IgG type) in testsamples. The assay utilizes the enzyme linked immunoabsorbenttechnique with selected immunogenic extracellular CaSR antigenand HRP labeled human IgG specific detection antibody.Assay standards, controls and prediluted patient samples are addedto microtiter wells of a microplate which is coated with a highlypurified human CaSR extracellular antigen. After the first incubationperiod, the CaSR antigen on the wall of microtiter well absorbs orcaptures human anti-CaSR autoantibody in the sample and unboundproteins in each microtiter well are washed away. Then a HRPconjugated polyclonal anti-human IgG antibody is added to eachmicrotiter well and a link of CaSR antigen - human anti-CaSRautoantibody - HRP conjugated detection antibody is formed. Theunbound detection antibody is removed in the subsequent washingstep. HRP conjugated detection antibody bound to the well is thenincubated with a substrate solution in a timed reaction and thenmeasured in a spectrophotometric microplate reader. The enzymaticactivity of the detection antibody bound to the human anti-CaSRautoantibody on the wall of the microtiter well is directly proportionalto the amount of this autoantibody in the sample. A standard curve isgenerated by plotting the absorbance versus the respectiveautoantibody concentration for each standard on point-to-point orcubical scales. The concentration of human anti-CaSR autoantibodyin test samples is determined directly from this standard curve.
    Reagent Preparation

    (1) Prior to use allow all reagents to come to room temperature. Regents from different kit lot numbers should not be combined or interchanged.
    (2) ELISA Wash Concentrate must be diluted to working solution prior

    Sample Collection
    Only 10 μL of human serum or plasma is required for human anti-CaSR autoantibody measurement. No special preparation of individual is necessary prior to specimen collection. Whole blood should be collected and must be allowed to clot for minimum 30 minutes at room temperature before the serum is separated by centrifugation (850 1500xg for 10 minutes). The serum should be separated from the clot within three hours of blood collection and transferred to a clean test tube. Serum samples should be stored at 20 °C or below until measurement.
    Sample Preparation

    Patient serum or plasma sample need to be diluted 1:100 with assay buffer before being measured.
    (1) Label one test tube (12x75 mm) for every patient sample
    (2) Add 1 mL of assay buffer to each tube
    (3) Pipet 10 μL of patient serum or plasma sample to correspondent test tube and mix well (1:100 dilution)

    Assay Procedure

    (1) Place a sufficient number of human CaSR antigen coated microwell strips in a holder to run human assay standards, controls and unknown samples in duplicate.
    (2) Test Configuration
    (3) Add 100 μL of standards, controls and 1:100 diluted patient samples into the designated microwell.
    (4) Mix gently and cover the plate with one plate sealer and also with aluminum foil to avoid exposure to light.
    (5) Incubate plate at room temperature for 60 minutes.
    (6) Prepare working Tracer Antibody Working Solution by 1:21 fold dilution of the Human CaSR Detection Antibody (Cat# 30184) with the Tracer Antibody Diluent. For each strip, it is required to mix 1 mL of Tracer Antibody Diluent with 50 μL of the detection antibody in a clean test tube.
    (7) Remove the aluminum foil and plate sealer. Aspirate the contents of each well. Wash each well 5 times by dispensing 350 μL of working wash solution into each well and then completely aspirating the contents. Alternatively, an automated microplate washer can be used.
    (8) Add 100 μL of above diluted detection antibody working solution to each of the wells.
    (9) Cover the plate with one plate sealer and also with aluminum foil to avoid exposure to light.
    (10) Incubate plate at room temperature for 30 minutes.
    (11) Remove the aluminum foil and plate sealer. Aspirate the contents of each well. Wash each well 5 times by dispensing 350 μL of working wash solution into each well and then completely aspirating the contents. Alternatively,an automated microplate washer can be used.
    (12) Add 100 μL of ELISA HRP Substrate into each of thewells.
    (13) Cover the plate with one plate sealer and also withaluminum foil to avoid exposure to light.
    (14) Incubate plate at room temperature for 20 minutes
    (15) Remove the aluminum foil and plate sealer. Add 100 μL ofELISA Stop Solution into each of the wells. Mix gently.
    (16) Read the absorbance at 450 nm within 10 minutes in amicroplate readerNOTE: to reduce the background, one can set theinstrument to dual wavelength measurement at 450 nmwith background wavelength correction set at 595 nm or620 nm or 630 nm.

    Calculation of Results
    1. Calculate the average absorbance for each pair ofduplicate test results
      2. Subtract the average absorbance of the STD 1 (0 U/mL)from the average absorbance of all other readings toobtain corrected absorbance
      3. The standard curve is generated by plotting the correctedabsorbance of all standard levels on the ordinate againstthe standard concentration on the abscissa using point-topointor log-log paper. Appropriate computer assisted datareduction programs may also be used for the calculation ofresults.
    Restrictions
    For Research Use only
  • Precaution of Use
    The reagents must be used in research laboratory and are for research use only. Source material from which reagents of bovine serum was derived in the contiguous 48 United States. It was obtained only from healthy donor animals maintained under veterinary supervision and found free of contagious diseases. Wear gloves while performing this assay and handle these reagents as if they are potential infectious. Avoid contact with reagents containing TMB, hydrogen peroxide, or sulfuric acid. TMB may cause irritation to skin and mucous membranes and cause an allergic skin reaction. TMB is a suspected carcinogen. Sulfuric acid may cause severe irritation on contact with skin. Do not get in eyes, on skin, or on clothing. Do not ingest or inhale fumes. Upon contact, flush with copious amounts of water for at least 15 minutes. Use Good Laboratory Practices.
    Storage
    4 °C
  • Debowska, Poleszczuk, Wojcik-Zaluska, Ksiazek, Zaluska: "Phosphate Kinetics During Weekly Cycle of Hemodialysis Sessions: Application of Mathematical Modeling." in: Artificial organs, (2015) (PubMed).

  • Target See all Anti-CaSR IgG (CaSR IgG) products
    Anti-CaSR IgG (CaSR IgG) (Anti-Calcium Sensing Receptor IgG Antibody (CaSR IgG))
    Abstract
    CaSR IgG Products
    Target Type
    Antibody, Antibody
    Background
    The human calcium-sensing receptor (CaSR) is a 1078 amino acidcell surface protein, which is predominantly expressed in theparathyroid glands and kidney. It is a member of the family of Gprotein-coupled receptors. The CaSR allows regulation ofparathyroid hormone (PTH) secretion and renal tubular calciumreabsorption in response to alterations in extracellular calciumconcentrations. Abnormalities of the CaSR are associated with bothhypercalcaemic and hypocalcaemic disorders.The human CaSR gene is located on chromosome 3q21.1 and lossof-function CaSR mutations have been reported in thehypercalcaemic disorders of familial benign hypocalciurichypercalcaemia(FHH, FBH or FBHH) and neonatal severe primaryhyperparathyroidism (NSHPT).CaSR auto-antibodies have been found in FHH patients who did nothave loss-of-function CaSR mutations, and in patients with anacquired form (i.e. autoimmune) of hypoparathyroidism. Autoimmunehypoparathyroidism can occur as an isolated clinical abnormality, aspart of autoimmune polyendocrinopathy syndrome (APS)-1 or as partof APS-2. APS-1 most commonly comprises mucocutaneouscandidiasis, hypoparathyroidism, and Addison's disease. APS-2includes two or more of the following: Addison's disease, Graves'disease, autoimmune thyroiditis, type 1 diabetes mellitus, primaryhypogonadism, myasthenia gravis, or celiac sprue. Studies havedemonstrated that CaSR autoantibody is present in about one thirdof the patients with isolated acquired hypoparathyroidism. On theother hand, it is also reported that some clinical primaryhypoparathyroidism can harbor autoantibodies to human CaSR.Therefore, there is a great clinical value of detecting this autoantibdyto assess the autoimmune origin of the disease.
You are here:
Support